---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063973"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T15:40:51.330549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics Q1 2025 net revenue $38.9M, record adj. EBITDA $6.2M, raises FY adj. EBITDA guidance to $4-12M

## Summary
- Net revenue of $38.9M, up 12.2% YoY; acute care franchise up 89.4% driven by ZYNRELEF (+60.4%).
- Record Q1 adjusted EBITDA of $6.2M; full-year adj. EBITDA guidance raised to $4-12M from $0-8M.
- Settled patent litigation with Mylan on CINVANTI/APONVIE; generic entry agreed for June 1, 2032.
- Cash and investments $50.7M; ZYNRELEF prefilled syringe development on track for early 2027 launch.
- NOPAIN Act took effect April 1; provides separate Medicare payment for non-opioids like ZYNRELEF.

## SEC filing metadata
- accession: 0000950170-25-063973
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/0000950170-25-063973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/hrtx-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063973
- JSON: https://secwatch.observer/filing/0000950170-25-063973.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.